Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Effect on Hypoglycaemic Counter-regulation in T2D
NCT02147431Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2014
- Primary completion
- May 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Change in mean glucagon concentration during hypoglycaemia at Day 213. Started May 2014; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02147431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02147431.